DexCom Stock: Is DXCM Underperforming the Healthcare Sector?

DexCom, Inc. (DXCM) is a San Diego-based medical technology company that developed innovative continuous glucose monitoring systems. The company trades at $33.2 billion, placing it in the large-cap category. DexCom's notable advantage is its real-time glucose data, aiding diabetes management and informed healthcare decisions. The company's competitive advantage lies in its innovative CGM technology and reputation for accuracy and reliability.

Its CGM systems integrate with insulin pumps, and the company's expanding market presence stems from robust revenue growth, improving profitability, and a strong cash position.

However, DXCM has underperformed the healthcare sector over the past 52 weeks. It has gained 8.8%, while its benchmark ETF, State Street Health Select Sector SPDR ETF (XLV), has returned 24.8%. Over the past three months, DXCM stock has climbed 21.1%, outperforming XLV's 12.7% growth. Despite trading above its 50-day and 200-day moving averages since mid-May, indicating an upward trend, the shares have slipped 5.1% from their 52-week high of $92.59 on August 24, 2026.

Analysts maintain a bullish outlook on DXCM. The stock has a consensus rating of "Strong Buy" from 29 covering analysts, with a mean price target of $93.11, suggesting a potential upside of 5.9% from the current price levels.